Michael D. Hambuchen, PharmD, PhD

Michael Hambuchen, PharmD., Ph.D
Instructor
Phone: (501) 526-5657
Fax: (501) 526-4618
hambuchenmichaeld@uams.edu

Education

PharmD. – College of Pharmacy, UAMS, 2007
Ph.D. – Department of Pharmacology and Toxicology, UAMS, 2013

Research Interests

My research is the area of protein-based medications, specifically anti-stimulant (methamphetamine and synthetic cathinone) monoclonal antibodies and vaccines. These novel biologics are promising for the treatments of medical problems caused by drugs of abuse. These are needed due to the limited efficacy of small molecule drug therapies for stimulant abuse. I am a member of a team of scientists under the leadership of Dr. Michael Owens in the Department of Pharmacology and Toxicology in the College of Medicine. This multidisciplinary team has been studying antibody-based treatments for drugs of abuse since the 1980’s. My particular interest involves developing new analytical methods (behavior, pharmacokinetics, cell culture, etc.) to test the efficacy of these monoclonal antibodies. In addition, I am interested in discovering combination therapies that can potentially increase the anti-drug effects relative to monotherapy.

Research Support

Current Research
NIH/NIDA R01 DA039195-01 (Instructor) PI: Owens (04/01/2015 – 03/31/2019)
“Pharmacology and Therapy for MDPV and alpha-PVP Like Drugs of Abuse”

Publications

Hambuchen MD, Hendrickson HP, Gunnell MG, McClenahan SJ, Ewing LE, Gibson DM, Berquist MD, Owens SM. The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats. Drug Alcohol Depend. 179:347-354, 2017 (PMID: 28844011).

Hambuchen MD, Hendrickson HP, Owens SM. Chiral determination of 3,4-methylenedioxypyrovalerone enantiomers in rat serum. Anal Methods. 9(4):609-617, 2017 (PMID: 28286575).

Hambuchen MD, Rüedi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies. Hum Vaccin Immunother. Sep;12(9):2240-8, 2016 (PMID: 27163775).

Hambuchen MD, Carroll FI, Rüedi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, Brieaddy LE, Pidaparthi RR, Owens SM. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. J Med Chem. Jun 11; 58(11):4665-77, 2015 (PMID: 25973614).

Milesi-Hallé A, Hambuchen MD, McMillan DE, Owens SM. The pharmacokinetics of methamphetamine self-administration in male and female rats. Drug Alcohol Depend. May 1;150:164-9, 2015 (PMID: 25796510).

Peterson EC, Hambuchen MD, Tawney RL, Gunnell MG, Cowell JL, Lay JO Jr, Blough BE, Carroll FI, Owens SM. Simple radiometric method for accurately quantitating epitope densities of hapten-protein conjugates with sulfhydryl linkages. Bioconjug Chem. Dec 17; 25(12):2112-5, 2014 (PMID: 25426820).

Hambuchen MD, Rüedi-Bettschen D, Williams DK, Hendrickson H, Owens SM. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period. Vaccine. Oct 29; 32(47):6213-9, 2014 (PMID: 25252196).

Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Hum Vaccin Immunother. 10(9):2638-47, 2014 (PMID: 25483484).

Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets. Dec; 10(8):892-8, 2011 (PMID: 22229314).

View Dr. Hambuchen’s Publication List